Many teenagers enter adulthood with significant risk factors for cardiovascular disease, and emerging adulthood is a key time to address these risks. Interventions such as health practices, lifestyle changes, and improved access to healthcare can help reduce the risk of developing future cardiovascular disease.
Researchers at the University of Houston College of Pharmacy have identified a potential therapeutic target to repair injured muscles. They discovered that fibroblast growth factor–inducible 14 (Fn14) plays a crucial role in regulating satellite cell stability and function, which are responsible for muscle growth, repair, and regenerat...
A new review highlights how breast cancer cells change their communication and growth patterns, helping tumors survive, spread, and resist treatment. The review explores disrupted signaling pathways, including PI3K/Akt/mTOR and RAS/RAF/MEK/ERK, which can promote tumor progression and resistance to treatment.
Researchers have discovered a potential new treatment for pulmonary fibrosis by targeting the Piezo2 receptor, which plays a critical role in stiffness-mediated profibrotic fibroblast phenotypes. Inhibiting Piezo2 expression or function may slow disease progression and offer new therapeutic options.
A growing body of evidence suggests a significant link between human papillomavirus (HPV) and heart disease. Researchers pooled data from nearly 250,000 patients in seven studies, finding HPV-positive individuals had a 40% higher likelihood of developing cardiovascular disease.
A new study found that treating aged mice with montelukast improved retinal health by reducing inflammation and boosting proteasome activity. This approach may offer a promising new way to slow age-related vision loss and protect eye health in older adults.
People with heart failure who can travel outside their home without assistance are less likely to be hospitalized or die within a year. Life-space mobility, a measure of how far patients move in their communities, is a reliable marker of risk for adverse outcomes in chronic diseases.
The University of Texas at Arlington has contributed 23 patents to UT System's total of 234, increasing by 15% over 2023. This recognition showcases the university's role in translating research into daily innovations.
A new drug therapy combination inhibiting FAK, RAF, and MEK enzymes has shown promise in prolonging survival rates for preclinical mouse models of metastatic melanoma. The study's findings suggest the oral treatment can both treat and prevent brain metastasis.
The Alliance for Genomic Discovery has completed sequencing 250,000 whole genomes, providing a comprehensive clinical genomic dataset. This data is being leveraged to accelerate drug target discovery and therapeutic research.
A recent study identifies 11 natural compounds that can inhibit the SARS-CoV-2 spike protein, including caffeine, which exhibits high binding stability and excellent solubility. The discovery highlights the potential of natural products in combating COVID-19 and demonstrates the versatility of widely known compounds like caffeine.
Researchers at the University of Zurich have developed a technology to test 25 antibodies simultaneously in a single mouse, greatly reducing the number of laboratory animals required. The method uses protein fragments as barcodes for analysis, allowing for high-quality preclinical data on multiple antibody candidates.
The study found that tunneling nanotube-like structures connect cells in the heart, enabling long-distance intercellular communication essential for heart formation. Disruption of these structures resulted in impaired ventricular wall morphogenesis and defective myocardial growth.
Cyclic peptides targeting FXR show promise in treating MASH by reducing intestinal ceramide production and promoting GLP-1 release. DC646 is the most potent FXR antagonist with a favorable safety profile.
Tirzepatide and semaglutide offer substantial long-term health benefits in US adults, reducing obesity risk. However, the high costs of these medications make them not cost-effective at current net prices, hindering equitable access.
Engineered platelets-based nano-aircraft carriers enhance targeted chemotherapy with graded drug release, promoting antitumor immune response and reducing metastasis. Researchers successfully develop Pts-based nanovesicles for precise cancer treatment.
Researchers have discovered how severe COVID-19 can destroy immune cells' ability to repair the lungs, leading to lingering effects of long COVID. By enhancing damaged organelles using a FDA-approved drug, they found improved lung healing and reduced inflammation.
Research from the Long Life Family Study found individuals from long-lived families have significantly better vascular health than the general population. The study identified key risk factors and four genomic regions linked to PAD risk, providing novel insight into underlying mechanisms.
A new type of antibody that stimulates the immune system to target cancer cells has shown promise in reducing tumor growth in treatment-resistant breast and ovarian cancers. The study found that the antibody, IgE, uniquely stimulated otherwise inactive immune cells to directly target HER2-expressing cancer cells.
The Crew-10 mission will support cutting-edge biomedical investigations and NSF-funded physical science projects through the ISS National Lab. Astronauts will conduct experiments on the International Space Station, with findings benefiting humanity and driving commerce in low Earth orbit.
Researchers used CRISPR to cut a single gene from cancer cells of head and neck tumors, resulting in the elimination of 50% of the tumors after 84 days. This groundbreaking study demonstrates that some genes are essential for cancer cell survival, making them excellent targets for CRISPR therapy.
Researchers have discovered a family of genes essential for tuberculosis survival during airborne transmission, providing new drug targets. The study sheds light on the bacterium's protective mechanisms, which could prevent infection spread and treat existing cases.
Researchers at Weill Cornell Medicine and MIT discovered a family of genes necessary for tuberculosis bacteria to survive airborne transmission. These genes help the bacteria adapt to changes in temperature, oxygen levels, and humidity, providing new targets for therapies that could treat infection and prevent spread.
Researchers at Vanderbilt University Medical Center aim to use artificial intelligence technologies to generate antibody therapies against specific antigen targets. The project, funded by $30 million from ARPA-H, will create a massive antibody-antigen atlas and develop AI-based algorithms to engineer antigen-specific antibodies.
A new study by researchers at UCSF has found that long-acting injectable treatments can be transformative for patients who struggle to take daily HIV pills, resulting in undetectable viral loads and improved health outcomes. The treatment approach could help stop the spread of HIV by keeping more patients from being infectious.
Magnetic nanoparticles are guided to tumors using a magnet and heated by a laser to destroy cancer cells. Researchers developed nanoparticles that outperform conventional photothermal agents, killing cancer cells with high efficiency.
The Aligning Science Across Parkinson’s (ASAP) initiative offers funding of up to $6M for research community members to develop sustainable tools for Parkinson’s disease research. The funding supports the development of preclinical models, detection reagents, and modulation agents to accelerate therapeutic research.
The new AI model leverages hypergraphs to quickly and accurately identify therapeutic gene targets for diseases. HIT outperformed existing models in all tested metrics, demonstrating its accuracy in classifying therapeutic gene targets with great precision.
Core-shell nanoparticles offer effective drug encapsulation, shielding from degradation, and controlled release. This innovation enables targeted drug delivery, improving treatment outcomes and reducing side effects. The versatility of these nanoparticles allows for tailored materials to suit different therapeutic needs.
Researchers at VCU Massey Comprehensive Cancer Center have identified an innovative combination treatment strategy that collaborates to kill AML cells. The new approach targets the SRC gene and MCL-1 protein, leading to increased cell death in leukemia cells. This discovery offers a promising new direction for leukemia treatment.
Researchers explore ataciguat to manage aortic valve stenosis, showing potential to significantly slow disease progression. The drug may enable a once-in-a-lifetime procedure by delaying valve replacement surgery.
Researchers have discovered several novel downstream p53 targets that could lead to improved cancer therapies. The study highlights the critical role of p53 in preventing cancer and identifies two new genes, ALDH3A1 and NECTIN4, as potential targets for cancer treatment.
The FDA has approved a new treatment for Parkinson's disease that can adjust to the individual's brain activity, providing precise stimulation. This technology, known as adaptive deep brain stimulation (aDBS), detects patterns of brain activity and delivers tailored electric pulses to reduce symptoms.
The University of Texas at Arlington is joining forces with the Texas A&M Engineering Experiment Station to operate a new biomanufacturing center. This partnership will expand UTA's capabilities and provide access to financial support and industry partners, enabling researchers to develop and commercialize production of new bioprod...
Recent research suggests that select athletes with cardiovascular abnormalities can safely participate in competitive sports after shared decision-making with their clinicians. The new scientific statement reviews best clinical practices for athletes with certain cardiovascular conditions and provides an evidence-based path for safe re...
A new study published in the Journal of Antimicrobial Chemotherapy has found that lenacapavir is effective in controlling HIV in a population of patients in Uganda. The study sequenced the capsid proteins from 546 Ugandan patients and found little natural resistance to the drug.
Scientists at Nagoya University have developed a new mRNA technology that can produce up to 200 times more protein than traditional methods. This breakthrough enables the creation of healthy proteins to treat illnesses or toxic proteins to kill unwanted cells.
Cancer cells work together to source nutrients from their environment, a cooperative process that can be targeted for treating cancer. Researchers identified key enzymes and mechanisms behind this cooperation, including the enzyme CNDP2, which can be inhibited by the drug bestatin.
Researchers at Virginia Tech have developed a method to convert gut bacteria into mini protein factories that produce and release sustained flows of targeted proteins within the lower intestine. This approach eliminates a major roadblock in delivering drugs to this part of the body, offering potential treatment for chronic diseases.
Researchers found that a combination of Panitumumab and low-dose Capecitabine is an effective and well-tolerated maintenance regimen for patients with wild-type KRAS metastatic colorectal cancer. The treatment delayed disease progression while managing side effects, improving patients' quality of life.
Researchers at University of Gothenburg have identified a critical mechanism to slow down Crohn's disease progression by repairing the protective barrier of the gut. By reinforcing the gut's natural defenses, new drug targets may be developed to treat the disease.
Researchers created optimized DNA hydrogels with fewer nucleic acids, achieving efficient and sustained drug release. The new hydrogel units showed prolonged persistence of at least 168 hours post-administration in mice, contributing to anti-tumor effects.
The Colorectal Cancer Alliance has awarded new grants to researchers, convened top scientists at the Cure CRC Summit, and launched K-SPY, a groundbreaking multi-center platform trial for high-risk colorectal cancer cases. The initiative aims to improve outcomes for millions affected by the disease.
Researchers at Virginia Tech have developed a way to convert gut bacteria into miniature protein factories that produce and release targeted proteins inside the lower intestine. This breakthrough could potentially treat chronic diseases.
A new study from the University of Pennsylvania School of Medicine has created a comprehensive genetic map of over 1,000 genes influencing kidney function, providing new insights into the causes of kidney disease. The researchers discovered that proximal tubule cells are a key
Researchers from the University of Gothenburg have made a breakthrough in understanding the role of protein tau in Alzheimer's disease. By identifying specific amino acid modifications that occur before thread-like fibrils form, scientists hope to develop complementary drugs to combat the disease.
Researchers found that clot-dissolving medication alteplase improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke. This breakthrough may provide hope for stroke patients worldwide who may not have access to clot-dissolving medications within the approved time window.
A large genetic dataset and multi-omics approach identified 58 novel drug targets for both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). The study highlights the importance of developing targeted therapies for both subtypes, which have limited therapeutic options.
The DISTAL trial found that endovascular therapy in addition to best medical therapy did not reduce disability more than clot-busting treatment alone for patients with medium distal vessel blockages. The study showed that mechanical clot removal was a safe option, but its benefits were uncertain.
A new drug-free intervention targets the root cause of progressive loss of neural function in SMA by gradually reawakening functionally silent motor neurons. Early results show improved leg muscle strength and walking in adults with SMA, regardless of symptom severity.
Researchers at Tokyo University of Science have found that opioid delta-receptor agonists can alleviate stress-induced IBS symptoms in a validated mouse model by targeting the central nervous system. The study suggests that these drugs could provide a more definitive solution for IBS with minimal adverse effects.
Researchers at the University of Cincinnati presented studies on intracerebral hemorrhage treatment eligibility, finding only 3% of patients are eligible for a minimally invasive procedure. Additionally, a study found racial disparities in stroke recovery, with Black individuals experiencing worse functional outcomes after ischemic str...
Researchers discovered that a topical ABT-263 treatment effectively reduces aged skin senescence markers, priming the skin for improved subsequent wound healing. The treatment also triggered inflammation, which surprisingly helped the healing process by 'waking up' the skin's repair systems.
A Texas A&M University researcher found that reducing alcohol consumption aligns with a harm reduction approach, which may be a more feasible approach for high-risk college drinkers. The study surveyed 822 high-risk college students and analyzed their intention to reduce drinking using the Theory of Planned Behavior.
A recent study found that Streptococcus anginosis, a common mouth bacteria, is abundant in the guts of people with acute stroke and linked to a worse prognosis. The researchers also discovered that levels of this bacteria were associated with increased mortality rates two years after stroke.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
A new algorithm proposes measuring quadriceps muscle mass for more accurate sarcopenia diagnosis, potentially leading to earlier detection and better treatment options. Ultrasound imaging is recommended as a cost-effective and practical solution for diagnosing sarcopenia in clinical settings.
Researchers used AI to identify genetic factors in Parkinson's disease progression and FDA-approved drugs that can be repurposed for treatment. The study found potential risk genes like SNCA and LRRK2, which are known to cause inflammation, and identified candidate drugs such as simvastatin.
A study found that people with delayed REM sleep have higher levels of toxic proteins amyloid and tau, and lower levels of healthy protein BDNF, which can increase the risk of developing Alzheimer's. Practicing healthy sleep habits may help mitigate this risk.
The team's novel technique enables high-throughput screening of nanoparticle shapes, sizes, and modifications, reducing associated screening costs. The research demonstrates the distinct preferences of tumour cells for certain nanoparticle configurations, enabling personalized cancer treatments that are safer and more effective.